Tonkon 2000.

Study characteristics
Methods	Multicenter, prospective DBRCT conducted in US Follow‐up: 12 wks Background ACEI? Yes
Participants	N=109 patients ≥18 years of age with stable symptomatic CHF, due to IHD (53%), idiopathic (40%), or other cause (7%), who were already receiving stable doses of ACEI (≥6 wks) and diuretics (≥2 wks) before and throughout study Mean age: 63.9 y Females: 23.9% Race (white/black/other): 82%/12%/6% NYHA Class: II–III LVEF: ≤40%
Interventions	Irbesartan, target dose 150 mg OD (n=57) Placebo (n=52)
Outcomes	Primary: Symptom‐limited exercise tolerance time Secondary: NYHA functional class; LVEF
Notes	Funding source: Bristol‐Myers Squibb Pharmaceutical Research Institute
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Low risk	Quote: "Double‐blind therapy was administered as capsules of irbesartan or matching placebo."
Incomplete outcome data (attrition bias) All outcomes	High risk	Missing outcome data, i.e. total hospitalisations Quote: "Data from all randomised patients were included in the safety analysis."
Other bias	High risk	Funding source is manufacturer of irbesartan.